Dry Powder Inhaler Market

How big is Dry Powder Inhaler Market in 2026?

The global dry powder inhaler market is estimated at USD 21.6 billion in 2025 and is expected to reach USD 22.4 billion in 2026. By 2036, the market is projected to reach USD 31.6 billion, expanding at a CAGR of 3.5% from 2026. According to FMI analysis, multi-dose inhalers lead product sales with an estimated 59.4% share in 2026.

Key drivers of the dry powder inhaler market include a large asthma population and a heavy COPD burden. WHO, for example, estimates that asthma affected 363 million people in 2023 [1]. As a result, repeat prescriptions for maintenance inhalers stay steady year after year. Sales of long-acting inhalers also depend on COPD care, and COPD caused 3.4 million deaths in 2023, about 6% of all global deaths [2]. Adoption of lower-carbon inhalers is also shifting device choice, as GSK reported positive phase III data on October 22, 2025 for a low carbon Ventolin using HFA-152a, with potential emission cuts of 92% per inhaler [3]. FMI analysis indicates that greener metered dose inhalers will compete harder with powder devices for new prescriptions.

Table 1: Dry Powder Inhaler Market Size and Forecast (USD billion), 2025 to 2036

Market size and forecast	Value
2025 market size	USD 21.6 billion
Estimated market size in 2026	USD 22.4 billion
Projected market size by 2036	USD 31.6 billion
CAGR (2026 to 2036)	3.5%
Added sales, 2026 to 2036	USD 9.2 billion

Key Market Trends & Insights

• By product: Multi-dose inhalers will hold 59.4% of 2026 sales, as maintenance patients prefer one device that holds a month of doses.
• By indication: Asthma is expected to account for 42.7% of 2026 sales, given the very large number of patients on daily controller therapy.
• By function: Manually operated devices are likely to hold an estimated 63.8% of 2026 sales, since most branded and generic powder inhalers still work without electronics.

Regional Highlights

• Fastest-growing country: India is expected to grow fastest, at a CAGR of 5.2% between 2026 and 2036, as low-cost local inhalers widen access to maintenance therapy.
• Growth across other countries: Demand in ASEAN, led by Indonesia, is set to grow at 4.7%, and China at 4.4% as triple therapy use widens, both above the 3.5% average. North America grows close to the global pace, with the United States at 3.3% and Canada at 3.1%. In Europe, Spain is expected to grow at 2.9%, and France has the slowest rate at 2.4%.

Uneven access to inhaled medicines determines which countries will provide new device volume. WHO reports that bronchodilators were available in public primary care in less than two thirds of low and lower-middle income countries in 2023 [1]. Steroid inhalers were available in less than half of those countries. Consequently, wider public supply in these countries would add large volumes of low-cost powder inhalers. COPD adds to that need, as nearly 90% of COPD deaths under age 70 occur in low and middle income countries [2]. Expanding primary care therefore remains the main route to new inhaler volume.

Commercial results show a split between growing triple therapies and pressure from generics. GSK reported second quarter 2026 Trelegy sales of GBP 0.8 billion, down 7% [4]. Lower sales of a leading powder inhaler signal price pressure in mature markets. By contrast, AstraZeneca reported first half 2026 Breztri revenue of USD 699 million, up 17% at constant exchange rates [5]. Symbicort revenue fell 4% at constant rates as a new generic competitor entered the US market. Generic entry thus lowers prices for older combinations, which shifts value toward newer triple therapies.

New approvals and biologics are changing treatment pathways. China approved Trelegy Ellipta for adults with uncontrolled asthma in January 2026, the only single inhaler triple therapy there for both asthma and COPD [6]. Approval for a second indication widens the patient pool for a once-daily powder device. Meanwhile, biologics are entering COPD care, as the US FDA approved Nucala as an add-on maintenance treatment for COPD with an eosinophilic phenotype in May 2025 [7]. Biologics are added to inhaler therapy and rarely replace inhalers, so maintenance inhaler demand holds up even as some high-cost treatment moves to injections.

Table 2: Supporting Industry Indicators for the Dry Powder Inhaler Market, 2023 to 2026

Indicator	Data point	Why it matters	Source
Asthma burden	An estimated 363 million people with asthma in 2023.	The patient pool sets maintenance inhaler demand.	[1]
Inhaler access	Bronchodilators available in public primary care in less than two thirds of low and lower-middle income countries in 2023.	Access gaps mark room for volume growth.	[1]
COPD burden	3.4 million COPD deaths in 2023, about 6% of global deaths.	COPD drives demand for long-acting inhalers.	[2]
Triple therapy sales	GSK Trelegy second quarter 2026 sales of GBP 0.8 billion, down 7%.	Price pressure is reaching leading powder brands.	[4]
Company outlook	GSK reaffirmed 2026 turnover growth guidance of 3% to 5% in July 2026.	Respiratory makers expect modest growth.	[4]
Respiratory sales	AstraZeneca first half 2026 Respiratory and Immunology revenue of USD 4,750 million, up 9% at CER.	Respiratory portfolios are still growing.	[5]
Generic entry	Symbicort revenue down 4% at CER in the first half of 2026 after a new US generic entered.	Generics cut prices for older combinations.	[5]
New indication	Trelegy Ellipta approved in China for adult asthma in January 2026.	New indications widen the powder inhaler patient pool.	[6]
Low carbon inhalers	Low carbon Ventolin with HFA-152a showed potential 92% emission cuts, October 2025.	Greener MDIs compete with powder devices.	[3]
Biologics in COPD	Nucala approved by the US FDA for eosinophilic COPD in May 2025.	Biologics add to, more than replace, inhaled therapy.	[7]
Clinical research	GSK presented 33 abstracts at ATS 2026, including single-inhaler triple therapy studies.	Ongoing evidence supports inhaled triple therapy use.	[8]

Demand Intensity Analysis

The asthma population gives the clearest patient benchmark. WHO estimated 363 million people with asthma in 2023 [1]. Dividing the 2025 market estimate of USD 21.6 billion by that asthma count gives about USD 59.5 of powder inhaler sales per patient. The market also covers COPD and other indications, so the true asthma value per patient is lower. Many patients go untreated or use only rescue inhalers, which leaves room for maintenance therapy to grow.

The asthma segment gives a narrower and closer comparison with patient numbers. At 42.7% of the 2026 estimate, asthma equals about USD 9.6 billion in sales. Spread across the 363 million people with asthma counted by WHO, that segment gives about USD 26.3 per patient [1]. Low per-patient value reflects large untreated populations in low income countries and cheap generic devices. Wider access would therefore raise volume faster than value.

The leading players in the dry powder inhaler market give a supply-side benchmark for inhaled respiratory value. AstraZeneca reported first half 2026 Respiratory and Immunology revenue of USD 4,750 million [5]. The 2026 market estimate is about 4.7 times that half-year figure. The scope differs, as the AstraZeneca unit includes biologics and metered dose inhalers, and the market covers many generic powder devices. Even so, a handful of large companies account for a big part of inhaled respiratory value.

Comparing growth rates shows how cautious the forecast is. AstraZeneca Respiratory and Immunology revenue grew 9% at constant exchange rates in the first half of 2026, and Breztri grew 17% [5]. The 3.5% market CAGR is 5.5 points below the respiratory unit growth rate. Generic price erosion on older combinations explains much of the gap, which the forecast assumes will persist.

Table 3: Demand Intensity Metrics for the Dry Powder Inhaler Market, 2023 to 2026 Data Against 2025 and 2026 Market Values

Demand intensity metric	Value	Basis
People with asthma, 2023	363 million	World Health Organization, April 2026 fact sheet
Sales per person with asthma	USD 59.5	Calculated from WHO asthma estimate and the 2025 market value
Asthma segment value, 2026	USD 9.6 billion	Calculated from the 42.7% asthma share and the 2026 market value
Asthma segment sales per person with asthma	USD 26.3	Calculated from WHO asthma estimate and the 2026 asthma segment value
COPD deaths, 2023	3.4 million	World Health Organization, June 2026 fact sheet
AstraZeneca Respiratory and Immunology revenue, first half 2026	USD 4,750 million	AstraZeneca, July 2026 results
2026 market value as a multiple of the AstraZeneca unit	4.7 times	Calculated from AstraZeneca results and the 2026 market value
AstraZeneca Respiratory and Immunology growth at CER	9%	AstraZeneca, first half 2026
Gap between the CAGR and respiratory unit growth	5.5 points	Calculated from the 3.5% CAGR and 9% growth
GSK Trelegy second quarter 2026 sales	GBP 0.8 billion, down 7%	GSK, July 2026 results

Analyst Perspective

“Dry powder inhalers are shifting from blockbuster combinations to a mix of generics and once-daily triple therapies. Growth will come from widening access in emerging markets more than from price. Low carbon propellant inhalers will compete hard for new patients, so powder device makers need to prove ease of use and lower total cost.”

Anurag Sharma, Principal Consultant, Future Market Insights.

How is the dry powder inhaler market segmented?

The market is segmented into product, indication, function, end user, and region. Multi-dose dry powder inhalers are expected to lead product with 59.4% share in 2026, and asthma leads indication with an estimated 42.7%.

By product: multi-dose dry powder inhalers and single-dose dry powder inhalers.

By indication: asthma, COPD, pulmonary arterial hypertension, diabetes, and cystic fibrosis.

By function: manually operated inhaler devices and digitally operated inhaler devices.

By end user: institutional sales, retail sales, and mail order pharmacies.

By region: inhaler prescriptions across North America, Latin America, Western Europe and Eastern Europe, plus East Asia, South Asia and Pacific, and the Middle East and Africa, each with distinct generic penetration.

Why do multi-dose devices lead the dry powder inhaler market by product?

Multi-dose dry powder inhalers are expected to lead product sales with 59.4% share in 2026, ahead of single-dose devices at an estimated 40.6%.

Table 4: Product Share for the Dry Powder Inhaler Market (percentage share), 2026

Product	Estimated Share (2026)
Multi-Dose Dry Powder Inhalers	59.4%
Single-Dose Dry Powder Inhalers	40.6%
Total	100.0%

Table 5: Product Leadership and Market Growth for the Dry Powder Inhaler Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	3.5%
Leading Segment	Multi-Dose Dry Powder Inhalers

Multi-dose inhalers are expected to hold 59.4% in 2026, as one device with a month of pre-metered doses suits daily maintenance. Prices of capsule devices are low, and single-dose devices, which load a capsule for each dose, hold an estimated 40.6% and dominate low-cost generic markets. Multi-dose formats carry branded triple and dual therapies, which raises value per device. Single-dose capsule inhalers, by contrast, win on price in emerging markets. Multi-dose devices are expected to keep the lead, with single-dose units gaining volume in emerging markets.

• Reservoir and pre-metered blister devices make up the multi-dose segment.
• Once-daily triple therapy relies mainly on multi-dose devices, and Trelegy Ellipta is taken once daily in a single inhalation from a dry powder inhaler [6]. Simple once-daily dosing supports adherence, which keeps multi-dose devices in maintenance care.

Why does asthma lead the dry powder inhaler market by indication?

Asthma is estimated to lead indication sales with 42.7% share in 2026, ahead of COPD at about 38.9% and cystic fibrosis near 7.6%.

Table 6: Indication Share for the Dry Powder Inhaler Market (percentage share), 2026

Indication	Estimated Share (2026)
Asthma	42.7%
COPD	38.9%
Cystic Fibrosis	7.6%
Pulmonary Arterial Hypertension	6.3%
Diabetes	4.5%
Total	100.0%

Asthma is estimated at 42.7% of 2026 sales, as hundreds of millions of patients need daily controller therapy. COPD, about 38.9%, is close behind and grows with ageing populations and smoking history. Cystic fibrosis holds near 7.6%, using inhaled antibiotics and mucolytics. Pulmonary arterial hypertension (6.3%) and diabetes (4.5%) remain niche uses of inhaled delivery. Precision approaches are spreading into respiratory care, with the personalized medicine market projected to grow at a 6.4% CAGR from 2026 to 2036, and FMI sees asthma keeping the lead.

• Inhaled corticosteroid, combination and triple therapy controllers make up asthma demand.
• Uncontrolled asthma remains common, and GSK says approximately 46 million adults in China have asthma, around half with uncontrolled symptoms [6]. Uncontrolled patients are the main target for step-up maintenance inhalers.

Why do manual devices lead the dry powder inhaler market by function?

Manually operated inhaler devices are expected to lead function sales with 63.8% share in 2026, ahead of digitally operated devices at an estimated 36.2%.

Table 7: Function Share for the Dry Powder Inhaler Market (percentage share), 2026

Function	Estimated Share (2026)
Manually Operated Inhaler Devices	63.8%
Digitally Operated Inhaler Devices	36.2%
Total	100.0%

Manually operated devices are expected to hold 63.8% in 2026, as most powder inhalers rely on the patient's breath alone. Popularity of dose-logging sensors gives digitally operated devices about 36.2%. Connected devices help doctors spot poor adherence, though cost and data rules limit payer adoption. Digital health tools are expanding overall, with the digital health market projected to grow at a 7.4% CAGR from 2025 to 2035. Manual devices are likely to keep the lead, with digital models gaining in specialist care.

• Breath-actuated reservoir, blister and capsule devices make up the manual segment.
• Clinical evidence keeps growing for inhaled triple therapy. GSK presented 33 abstracts at ATS 2026, including single-inhaler triple therapy studies in COPD and asthma [8]. New data support continued prescribing of once-daily devices.

Why does retail lead the dry powder inhaler market by end user?

Retail sales are estimated to lead end user sales with 46.3% share in 2026, ahead of institutional sales at about 38.4% and mail order pharmacies near 15.3%.

Table 8: End User Share for the Dry Powder Inhaler Market (percentage share), 2026

End User	Estimated Share (2026)
Retail Sales	46.3%
Institutional Sales	38.4%
Mail Order Pharmacies	15.3%
Total	100.0%

Retail sales are estimated at 46.3% of 2026 sales, as patients refill maintenance inhalers at community pharmacies. Key trends in prescribing show that hospital pharmacies and specialty clinics start many patients on therapy, which gives institutional sales about 38.4%. Mail order pharmacies hold near 15.3%, serving long-term patients on repeat prescriptions. Accordingly, FMI sees retail keeping the lead, with mail order gaining as payers push home delivery.

• Community pharmacies and drug store chains make up retail sales.
• Generic entry is reshaping pharmacy dispensing, as AstraZeneca reported that a new generic competitor to Symbicort entered the US market, with brand revenue down 4% at CER in the first half of 2026 [5]. Generic substitution at the pharmacy counter lowers the value per prescription.

What are the drivers, restraints, and opportunities in the dry powder inhaler market?

Large asthma and COPD populations keep maintenance inhaler demand steady. Generic price erosion and low carbon metered dose inhalers limit value growth, and access programmes in emerging markets open new volume.

• Driver: Hundreds of millions of patients need daily controller therapy, and powder inhalers need no propellant and suit once-daily dosing.
• Restraint: Generic versions of older combinations cut prices, and lower-carbon propellant inhalers compete for new prescriptions.
• Opportunity: Wider public supply of inhalers in low and middle income countries and new indications open large new patient groups.

Large Patient Populations Sustain Demand

A very large number of patients with chronic airway disease supports powder inhaler volume. WHO estimates that asthma caused 442,000 deaths, with 363 million people affected in 2023 [1]. Patients on daily controllers refill inhalers every month, which creates predictable volume. As a result, maintenance demand will stay firm through 2036, even as prices fall.

Generics and Greener MDIs Limit Value Growth

Falling prices for older combinations are the main brake on market value. Second quarter 2026 Trelegy sales at GSK came in 7% lower than a year earlier [4]. Lower sales for a leading branded powder inhaler reflect competition and pricing pressure. Consequently, value growth will lag volume growth, and makers of older combinations will face the steepest declines. Metered dose devices remain a large alternative, with the metered dose inhalers market projected to grow at a 4.5% CAGR from 2026 to 2036.

Access Programmes Open New Volume

In low income countries, maintenance inhaler use remains limited. WHO reports that steroid inhalers were available in public primary care in less than half of low and lower-middle income countries in 2023 [1]. Closing that gap would bring millions of new patients onto daily therapy. Low-cost capsule devices are best placed to serve these markets, which supports single-dose volume growth.

Which country CAGRs are profiled in the dry powder inhaler market?

Table 9: Country CAGR Comparison for the Dry Powder Inhaler Market (CAGR percentage), 2026 to 2036

Country	CAGR
India	5.2%
ASEAN	4.7%
China	4.4%
United States	3.3%
Canada	3.1%
Spain	2.9%
France	2.4%

How do country-level CAGRs compare in the dry powder inhaler market?

India has the highest FMI inhaler growth rate, 5.2% a year against 3.5% globally, as local makers supply cheap capsule devices. ASEAN (4.7%) and China (4.4%) also grow faster than the global rate, as diagnosis and access improve. American powder inhaler sales hover near the average at 3.3%. Canada (3.1%), Spain (2.9%) and France (2.4%) grow below the global rate, as generics and greener metered dose inhalers limit value growth. The wider inhaler device sector grows at a similar pace, with the respiratory inhaler devices market projected at a 4.5% CAGR from 2026 to 2036.

• Local generic makers in India supply low-cost capsule inhalers, which widens access in public and private care.
• In ASEAN, air pollution and rising diagnosis raise demand, especially in Indonesia.
• China is adding indications for triple therapy, which widens the patient pool for once-daily devices.
• The United States faces new generic entry, so volume growth is offset by lower prices.
• Canada has a stable maintenance market, with generics capturing more prescriptions.
• Spain combines high COPD prevalence with strong generic use, which caps value growth.
• France encourages low-cost and lower-carbon prescribing, which slows powder inhaler value growth.

Full report country CAGRs cover: powder inhaler growth for India, ASEAN, China, the United States, Canada, Spain and France, ranging from 5.2% to 2.4%, and each other standard country in the regional tables.

Country-wise Analysis

India Dry Powder Inhaler Market Outlook (2026 to 2036)

Consumption of inhalers in India is supported by a very large asthma and COPD population and strong local manufacturing. Use of low-cost capsule devices makes maintenance therapy affordable for more patients. FMI expects Indian powder inhaler demand to rise at a 5.2% CAGR, ahead of all profiled markets.

Key takeaway: Indian patients can afford maintenance therapy as local makers sell cheap capsule inhalers, which makes India the fastest-growing market for powder devices.

ASEAN Dry Powder Inhaler Market Outlook (2026 to 2036)

Southeast Asia has rising air pollution and growing diagnosis of chronic airway disease. Supply of inhalers through public health systems is growing as more inhalers are added to essential medicine lists. Inhaler sales across ASEAN are forecast to grow at a 4.7% CAGR through 2036.

Key takeaway: Doctors in Southeast Asia are diagnosing more asthma and COPD, and public clinics are stocking more inhalers, so prescriptions for powder devices will rise.

China Dry Powder Inhaler Market Outlook (2026 to 2036)

Many of the adults with asthma in China have uncontrolled symptoms. Trelegy Ellipta gained approval in China for adult asthma in January 2026, adding to an existing COPD licence [6]. A second indication widens use of once-daily powder therapy. With new triple therapy indications, Chinese powder inhaler demand is expected to grow 4.4% a year.

Key takeaway: Chinese doctors can now prescribe a once-daily triple inhaler for adult asthma as well as COPD, which widens the group of patients using powder devices.

United States Dry Powder Inhaler Market Outlook (2026 to 2036)

The United States is the largest value market, but generics are entering. AstraZeneca reported that a new generic Symbicort competitor entered the US market in the first half of 2026 [5]. Generic entry lowers prices for older combinations sold at the pharmacy counter. FMI expects American powder inhaler sales to grow at a 3.3% CAGR as generics spread.

Key takeaway: American patients are switching to cheaper generic inhalers, so sales volumes in the United States will grow faster than sales value.

Canada Dry Powder Inhaler Market Outlook (2026 to 2036)

Buyers of maintenance inhalers in Canada are mostly public drug plans in a mature market. Provincial plans favour lower-cost generics as inhaler patents expire. With provincial plans keeping costs down, Canadian inhaler sales are projected to grow at a CAGR of about 3.1%.

Key takeaway: Provincial drug plans in Canada favour lower-cost generic inhalers, so value growth will stay modest even as patient numbers rise.

Spain Dry Powder Inhaler Market Outlook (2026 to 2036)

Supply of generic inhalers is strong in Spain, which has a large COPD population. Consumption of inhalers grows with ageing patients, and prices fall at the same time. Spanish powder inhaler value is expected to grow at a 2.9% CAGR.

Key takeaway: Spain has many ageing COPD patients who need daily inhalers, so volume will keep growing even as generic prices fall.

France Dry Powder Inhaler Market Outlook (2026 to 2036)

Buyer preference in France is shaped by policies that favour low-cost and lower-carbon inhalers. Low carbon metered dose inhalers, expected to launch from 2026, will compete for new patients [3]. Greener propellant devices may slow switching to powder inhalers. As doctors in France prescribe greener inhalers, sales of powder devices are projected to grow at a CAGR of only 2.4%, the slowest of the group.

Key takeaway: French doctors are encouraged to prescribe lower-cost and lower-carbon inhalers, so new low carbon metered dose devices may slow growth of powder inhalers.

Who are the notable companies in the dry powder inhaler market?

The profiled branded leaders are GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim and Chiesi Farmaceutici. Lower-priced powder combinations come from generic makers Teva Pharmaceutical Industries, Cipla, Mylan, Elpen, Beximco Pharmaceuticals and Sava Healthcare. Inhaler devices and powder formulations are supplied by Vectura Group, Hovione, AptarGroup, Iconovo (Stevanato Group), MannKind and Pharmaxis.

Originator respiratory companies, generic makers and device and formulation specialists compete across the market. Originators are defending share with triple therapies, and AstraZeneca grew Breztri 17% at CER in the first half of 2026 [5]. Strong growth in newer combinations offsets erosion of older brands, which keeps originators ahead in value. Cipla, Teva and Mylan compete on generic combinations, and FMI views device design and low cost as the main advantages for generic makers. Hovione, AptarGroup, Iconovo and Vectura supply formulation and device technology to both groups.

• Originator respiratory companies with branded dual and triple inhalers: GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim and Chiesi Farmaceutici.
• Generic and regional makers selling lower-priced powder combinations: Teva Pharmaceutical Industries, Cipla, Mylan, Beximco Pharmaceuticals, Elpen and Sava Healthcare.
• Device, formulation and specialty firms: Hovione, AptarGroup, Iconovo (Stevanato Group), Vectura Group, MannKind and Pharmaxis.

Competitive Benchmarking: Dry Powder Inhaler Market

Table 10: Competitive Benchmarking for the Dry Powder Inhaler Market (qualitative ratings), 2026

Company	Triple and Dual Therapies	Generic Range	Device Technology	Recent Activity
GlaxoSmithKline	High	Low	High	High
AstraZeneca	High	Low	Medium	High
Chiesi Farmaceutici	High	Low	High	Medium
Teva Pharmaceutical Industries	Medium	High	Medium	Low
Cipla	Medium	High	Medium	Medium
Hovione	Low	Low	High	Low

Ratings compare the companies on triple and dual therapies, generic range, device technology and recent activity.

Key Developments in the Dry Powder Inhaler Market

• GSK reaffirmed 2026 turnover growth guidance of 3% to 5% in July 2026, even as Trelegy sales fell 7% in the quarter [4].
• AstraZeneca reported a 17% rise in Breztri revenue at CER for the first half of 2026, confirming demand for triple therapy [5].
• In January 2026, China approved Trelegy Ellipta for adult asthma, widening use of a once-daily powder device [6].
• On October 22, 2025, GSK announced positive phase III data for a low carbon Ventolin, a step that raises competition from greener metered dose inhalers [3].
• WHO updated the COPD fact sheet in June 2026, reporting 3.4 million deaths in 2023 and underlining the need for maintenance therapy [2].
• GSK presented 33 abstracts at ATS 2026 in May 2026, adding evidence on single-inhaler triple therapy [8].
• The US FDA approved Nucala for eosinophilic COPD in May 2025, adding a biologic option alongside inhalers [7].

Key Players in the Dry Powder Inhaler Market

Originator Respiratory Companies

• GlaxoSmithKline
• AstraZeneca
• Novartis
• Boehringer Ingelheim
• Chiesi Farmaceutici

Generic and Regional Makers

• Teva Pharmaceutical Industries
• Cipla
• Mylan
• Beximco Pharmaceuticals
• Elpen
• Sava Healthcare

Device, Formulation and Specialty Firms

• Hovione
• AptarGroup
• Iconovo (Stevanato Group)
• Vectura Group
• MannKind
• Pharmaxis

Dry Powder Inhaler Market - Report Scope

Table 11: Report Scope for the Dry Powder Inhaler Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Product; indication; function; end user; region
Quantitative units	USD billion
Market definition	Single-dose and multi-dose dry powder inhalers, with the medicines inside, used for asthma, COPD and other conditions.
Regions covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries covered	United States; Canada; Brazil; Mexico; Argentina; Chile; Germany; France; United Kingdom; Italy; Spain; Benelux; Nordics; Poland; Czech Republic; Romania; Hungary; China; Japan; South Korea; India; ASEAN; Australia and New Zealand; GCC Countries; South Africa; Türkiye; Israel
Key companies profiled	GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceutical Industries, Boehringer Ingelheim, Cipla, Chiesi Farmaceutici, Elpen, Vectura Group, Beximco Pharmaceuticals, Hovione, AptarGroup, Iconovo (Stevanato Group), Sava Healthcare, MannKind, Mylan, Pharmaxis
Forecast period	2026 to 2036

Dry Powder Inhaler Market - Research Methodology

Table 12: Research Methodology for the Dry Powder Inhaler Market (research methods and approach), 2026 edition

Method	Approach
Data Sources	Company results, industry associations, government statistics and trade publications.
Desk Research	Disease burden, inhaler access, generic entry, propellant transition and respiratory pipelines.
Market Sizing	Sizing combines patient numbers, treatment rates and prices across products, indications and regions.
Data Validation	Figures are cross-checked across company, industry and government sources.

Dry Powder Inhaler Market by Segments

Dry Powder Inhaler Market segmented by Product:

• Multi-Dose Dry Powder Inhalers
• Single-Dose Dry Powder Inhalers

Dry Powder Inhaler Market segmented by Indication:

• Asthma
• COPD
• Pulmonary Arterial Hypertension
• Diabetes
• Cystic Fibrosis

Dry Powder Inhaler Market segmented by Function:

• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices

Dry Powder Inhaler Market segmented by End User:

• Institutional Sales
• Retail Sales
• Mail Order Pharmacies

Dry Powder Inhaler Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] World Health Organization. (2026, April 28). Asthma. https://www.who.int/news-room/fact-sheets/detail/asthma
• [2] World Health Organization. (2026, June 10). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
• [3] GSK plc. (2025, October 22). GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-next-generation-low-carbon-version-of-ventolin-salbutamol-metered-dose-inhaler/
• [4] GSK plc. (2026, July 28). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/
• [5] AstraZeneca PLC. (2026, July 27). AstraZeneca results: H1 and Q2 2026. https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-announcement.pdf
• [6] GSK plc. (2026, January 23). Trelegy Ellipta approved in China for use in adults with uncontrolled asthma. https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-in-china/
• [7] GSK plc. (2025, May 22). Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD). https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-by-us-fda/
• [8] GSK plc. (2026, May 6). GSK presents latest respiratory research to advance patient care at ATS 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-presents-latest-respiratory-research-to-advance-patient-care-at-ats-2026/

This bibliography is provided for reader reference. The full report contains the complete reference list and detailed citations.

This Report Answers

• How big is the dry powder inhaler market during 2026?
• What market size is projected by 2036?
• Which product holds notable share?
• Which indication holds notable share?
• Which countries have notable growth?
• Which companies are notable in the market?